78 results found.

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Case Comprehensive Cancer Center - Recruiting 18 years to 70 years.
- A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML).
bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Leukemia, Myeloid, Acute Clinical Trial using Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia.
Volasertib

Leukemia, Myeloid, Acute Clinical Trial using placebo; volasertib; low dose cytarabine

Boehringer Ingelheim - Recruiting N/A or older.
- A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy.
placebo; volasertib; low dose cytarabine

Leukemia, Myeloid, Acute Clinical Trial using decitabine iv; volasertib iv infusion

Boehringer Ingelheim - Recruiting 60 years or older.
- An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia.
decitabine iv; volasertib iv infusion

Disorder Related to Bone Marrow Transplantation, Leukemia, or Tra Clinical Trial using Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 3 years to 70 years.
- A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

Myeloproliferative Neoplasms Clinical Trial using Ruxolitinib; Decitabine

Mount Sinai School of Medicine - Recruiting 18 years or older.
- Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML.
Ruxolitinib; Decitabine

Acute Myeloid Leukemia Clinical Trial using IPH2102 at 0.1 mg/kg; IPH2102 at 1 mg/kg; Placebo (normal saline solution)

Innate Pharma - Recruiting 60 years to 80 years.
- Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission.
IPH2102 at 0.1 mg/kg; IPH2102 at 1 mg/kg; Placebo (normal saline solution)

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 2 years or older.
- A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML.
clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Leukemia Clinical Trial using Clofarabine; Idarubicin; Cytarabine; Fludarabine

M.D. Anderson Cancer Center - Recruiting 18 years to 60 years.
- Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.
Clofarabine; Idarubicin; Cytarabine; Fludarabine

Leukemia Clinical Trial using Cladribine; Cytarabine; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Cladribine; Cytarabine; Decitabine

Acute Myelogenous Leukemia, AML, or Acute Myeloid Leukemia Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML).
ABT-199

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial using Treosulfan

Center for International Blood and Marrow Transplant Research - Recruiting N/A to 21 years.
- A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation.
Treosulfan

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 80 years.
- Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study.

Myelodysplastic Syndromes (MDS), or Acute Myelogenous Leukemia (A Clinical Trial using low dose 5'-azacitidine

Memorial Sloan-Kettering Cancer Center - Recruiting 1 year to 75 years.
- A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse.
low dose 5'-azacitidine

Acute Myeloid Leukemia Clinical Trial using DAC; CLAG; Consolidation, I HAM cycle; II Consolidation HiDAraC; Consolidation, III HiDAraC cycle

Polish Adult Leukemia Group - Recruiting 18 years to 60 years.
- Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells.
DAC; CLAG; Consolidation, I HAM cycle; II Consolidation HiDAraC; Consolidation, III HiDAraC cycle

Myelogenous Leukemia, Acute Clinical Trial using RO5503781; cytarabine; Anthracycline

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML).
RO5503781; cytarabine; Anthracycline

Myelogenous Leukemia, Acute Clinical Trial using RO5429083; cytarabine

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML)..
RO5429083; cytarabine

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 74 years.
- Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML).
pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Bone Marrow Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation.
fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using standard follow-up care; medical chart review; quality-of-life assessment

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 75 years.
- Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML.
standard follow-up care; medical chart review; quality-of-life assessment

Acute Myeloid Leukemia (AML), or Acute Lymphocytic Leukemia (ALL) Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia.
CB-839

Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, B Clinical Trial using Clofarabine; Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Clofarabine; Lenalidomide

Acute Myeloid Leukemia Clinical Trial using pracinostat with azacitadine

MEI Pharma, Inc. - Recruiting 65 years or older.
- A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
pracinostat with azacitadine

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate.
pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Leukaemia, Acute Clinical Trial using Daunorubicin; Cytarabine; Eltrombopag; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy.
Daunorubicin; Cytarabine; Eltrombopag; Placebo

Leukemia Clinical Trial using Quizartinib; Cytarabine; AZA

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase I/Phase II.
Quizartinib; Cytarabine; AZA

Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis.
laboratory biomarker analysis

Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using WT1 peptide vaccine

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL).
WT1 peptide vaccine

Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; cyclosporine; methotrexate; methylprednisolone; tacrolimus; laboratory biomarker analysis; pharmacological study; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation

Children's Oncology Group - Recruiting N/A to 30 years.
- Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study.
anti-thymocyte globulin; busulfan; cyclophosphamide; cyclosporine; methotrexate; methylprednisolone; tacrolimus; laboratory biomarker analysis; pharmacological study; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation

Acute Myelogenous Leukemia Clinical Trial using MLN4924 and azacitidine

Millennium Pharmaceuticals, Inc. - Recruiting 60 years or older.
- A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Na‹ve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older.
MLN4924 and azacitidine

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 60 years.
- A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML).
cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

High Risk Acute Myeloid Leukemia Clinical Trial using CPX-351; 7+3 (cytarabine and daunorubicin)

Celator Pharmaceuticals - Recruiting 60 years to 75 years.
- Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML.
CPX-351; 7+3 (cytarabine and daunorubicin)

Acute Myeloid Leukemia Clinical Trial using PGX-ODSH-2013-AML-1

Cantex Pharmaceticals - Recruiting 18 years to 80 years.
- A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia.
PGX-ODSH-2013-AML-1

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 16 years to 50 years.
- A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome.
iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Acute Myeloid Leukemia Clinical Trial using AZD1208

AstraZeneca - Recruiting 18 years or older.
- A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).
AZD1208

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using caspofungin acetate; fluconazole; laboratory biomarker analysis

Children's Oncology Group - Recruiting 3 Months to 30 years.
- A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML).
caspofungin acetate; fluconazole; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study.
decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Acute Myeloid Leukemia Clinical Trial using Multiplex respiratory viral PCR

Centre Hospitalier Universitaire, Amiens - Recruiting 18 years to 85 years.
- Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy.
Multiplex respiratory viral PCR

Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, A Clinical Trial using Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors.
Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Acute Myeloid Leukemia Clinical Trial using GRASPA

ERYtech Pharma - Recruiting 65 years to 85 years.
- A Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients, Over 65 Years, Unfit for Intensive Chemotherapy..
GRASPA

Pediatric Acute Myeloblastic Leukemia Clinical Trial using Randomisation course 1 mitoxantrone versus DaunoXome; Randomisation course 2 ADxE versus FLADx

Vastra Gotaland Region - Recruiting N/A to 18 years.
- NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years.
Randomisation course 1 mitoxantrone versus DaunoXome; Randomisation course 2 ADxE versus FLADx

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Acute Myelogenous Leukemia (AML) Clinical Trial using MK-8242; cytarabine

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005)).
MK-8242; cytarabine

MDS, CMML, or AML Clinical Trial using SGI-110

Astex Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).
SGI-110

Acute Myeloid Leukemia Clinical Trial using Midostaurin (PKC412); Standard of Care

Novartis - Recruiting 18 years to 60 years.
- A Phase II, Randomized, Comparative Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia.
Midostaurin (PKC412); Standard of Care

AML Subjects Who Have Failed Prior Systemic Therapy Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 18 years or older.
- Phase 2 Study of ADI-PEG 20 in Relapsed/Refractory Acute Myeloid Leukemia.
ADI-PEG 20

Leukemia Clinical Trial using Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML).
Decitabine

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS.
cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML).
daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using lenalidomide; laboratory biomarker analysis

Albert Einstein College of Medicine of Yeshiva University - Recruiting 60 years to 75 years.
- A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML).
lenalidomide; laboratory biomarker analysis

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), My Clinical Trial using Sorafenib; Cytarabine; Clofarabine

St. Jude Children's Research Hospital - Recruiting N/A to 31 years.
- A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies.
Sorafenib; Cytarabine; Clofarabine

Leukemia Clinical Trial using E7070; Idarubicin; Cytarabine; Dexamethasone

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes.
E7070; Idarubicin; Cytarabine; Dexamethasone

Acute Myeloid Leukemia, or Myelodysplastic Syndromes Clinical Trial using CD8+ T-cell depleted donor lymphocyte infusion

National University Hospital, Singapore - Recruiting 21 years to 90 years.
- Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS).
CD8+ T-cell depleted donor lymphocyte infusion

Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Clinical Trial using asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A to 29 years.
- A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD.
asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using decitabine

Washington University School of Medicine - Recruiting 18 years or older.
- Genomic Predictors of Decitabine Response in AML/MDS.
decitabine

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML.
WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), A Clinical Trial using NiCordr

Gamida Cell ltd - Recruiting 18 years to 65 years.
- Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adult Patients With Hematological Malignancies.
NiCordr

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblast Clinical Trial using azacitidine; cytarabine; mitoxantrone hydrochloride; laboratory biomarker analysis

University of Chicago - Recruiting 18 years or older.
- Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML).
azacitidine; cytarabine; mitoxantrone hydrochloride; laboratory biomarker analysis

Acute Myeloid Leukemia Clinical Trial using Sorafenib

Massachusetts General Hospital - Recruiting 18 years to 75 years.
- Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation.
Sorafenib

Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MD Clinical Trial using Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Allogeneic Transplant for Hematological Malignancy.
Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Acute Myeloid Leukemia Clinical Trial using midostaurin (PKC412)

Technische Universit„t Dresden - Recruiting 18 years to 65 years.
- A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML.
midostaurin (PKC412)

Acute Myelogenous Leukemia Clinical Trial using dasatinib (SPRYCEL); all trans retinoic acid (VESANOID)

University of Pittsburgh - Recruiting 18 years or older.
- A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia.
dasatinib (SPRYCEL); all trans retinoic acid (VESANOID)

Leukemia, or Myelodysplastic Syndromes Clinical Trial using clofarabine; cytarabine; idarubicin

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 60 years.
- Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial).
clofarabine; cytarabine; idarubicin

Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, or Non- Clinical Trial using Fenretinide; Cytarabine; Methotrexate

South Plains Oncology Consortium - Recruiting N/A to 21 years.
- A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058'.
Fenretinide; Cytarabine; Methotrexate

Acute Myeloid Leukemia Clinical Trial using Exercise; Control

University Health Network, Toronto - Recruiting 18 years or older.
- A Phase II Exercise RCT for AML Patients Undergoing Induction Chemotherapy.
Exercise; Control

Acute Myeloid Leukaemia Clinical Trial using Cytarabine

University of Leipzig - Recruiting 18 years to 60 years.
- Randomised Comparison of OSHO Induction vs. the German AML Intergroup Standard, Randomised Comparison of AraC/Mtx vs. Flu/AraC/Mtx in Pts Without CR After One Induction Cycle and Randomized Comparison of One vs. Two Consolidation Therapies..
Cytarabine

Acute Myeloid Leukemia Clinical Trial using plerixafor; decitabine

Weill Medical College of Cornell University - Recruiting 60 years or older.
- Induction Therapy With Decitabine and Plerixafor Priming for Patients ò 60 Years With Acute Myeloid Leukemia.
plerixafor; decitabine

Acute Myeloid Leukemia Clinical Trial using Revlimid

University Health Network, Toronto - Recruiting 18 years or older.
- A Randomized Phase II Study of Lenalidomide Maintenance Therapy in AML Patients Aged > 60 Years in CR1 or Higher and < 60 Years in CR2 or Higher.
Revlimid

Acute Myeloid Leukemia Clinical Trial using FLAG+IDA

Cooperative Study Group A for Hematology - Recruiting 15 years to 60 years.
- Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia.
FLAG+IDA

AML Clinical Trial using Glivec; Mitoxantrone; Topotecan; AraC

Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older.
- Open-Label Multicenter Trial of Glivecr (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML).
Glivec; Mitoxantrone; Topotecan; AraC

Acute Myeloid Leukemia, or Elderly Clinical Trial using Azacitidine

Kansas City Veteran Affairs Medical Center - Recruiting 60 years or older.
- A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study.
Azacitidine

Leukemia, Myeloid, Acute Clinical Trial using RFUSIN2-AML1; Donor leukocyte infusion (DLI); RFUSIN2-AML1 and donor leukocyte infusion

King's College Hospital NHS Trust - Recruiting 18 years or older.
- A Phase I Study of Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) Expressing B7.1 (CD80) and IL-2 for the Potential Enhancement of Graft Versus Leukaemia(GvL) Effect in Poor Prognosis AML.
RFUSIN2-AML1; Donor leukocyte infusion (DLI); RFUSIN2-AML1 and donor leukocyte infusion